1. Search Result
Search Result
Results for "

pMEK

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-137092
    IACS-13909
    3 Publications Verification

    SHP2 Phosphatase Cancer
    IACS-13909 is a selective, potent and orally active SHP2 allosteric inhibitor with an IC50 of 15.7 nM and a Kd of 32 nM. IACS-13909 is more selective for SHP2 than other phosphatases (including SHP1). IACS-13909 has antitumor activities and suppresses MAPK pathway signaling in receptor tyrosine kinases (RTK)-dependent cancers .
    IACS-13909
  • HY-146223

    Ras p38 MAPK PI3K Apoptosis Cancer
    AZD4625 is an orally active, selective irreversible, covalent allosteric GTPase KRASG12C inhibitor with an IC50 of 3 nM. AZD4625 can inhibit the MAPK pathway (with decreased pCRAF, pMEK, and pERK) and the PI3K pathway (with decreased pAKT and pS6), and induce cell apoptosis. AZD4625 has no binding and inhibition of wild-type RAS or isoforms carrying non-KRASG12C mutations. AZD4625 can be used for the study of KRASG12C mutant non-small cell lung cancer .
    AZD4625
  • HY-136420

    PROTACs Raf Apoptosis Cancer
    SJF-0628 is a RAF PROTAC degrader. SJF-0628 induces targeted degradation of BRAF in various cancer cell lines (colorectal cancer cell lines (Colo-205, LS-411N, HT-29, RKO) and triple-negative breast cancer cell line DU-4475). SJF-0628 decreases pMEK and pErk levels in DU-4475 cells. SJF-0628 has anti-tumor activity. SJF-0628 can be used for research of colorectal cancer and triple-negative breast cancer. (Pink: RAF ligand (HY-12057), Blue: VHL Ligand ( HY-125845), Black: Linker (HY-B0912)) .
    SJF-0628
  • HY-146223A

    Ras PI3K p38 MAPK Apoptosis Cancer
    (3R,10R,14aS)-AZD4625 is the isomer of AZD4625 (HY-146223), and can be used as an experimental control. AZD4625 is an orally active, selective irreversible, covalent allosteric GTPase KRASG12C inhibitor with an IC50 of 3 nM. AZD4625 can inhibit the MAPK pathway (with decreased pCRAF, pMEK, and pERK) and the PI3K pathway (with decreased pAKT and pS6), and induce cell apoptosis. AZD4625 has no binding and inhibition of wild-type RAS or isoforms carrying non-KRASG12C mutations. AZD4625 can be used for the study of KRASG12C mutant non-small cell lung cancer .
    (3R,10R,14aS)-AZD4625
  • HY-143468

    Apoptosis MEK Cancer
    MEK-IN-5 is a potent MEK inhibitor and NO donor. MEK-IN-5 significantly reduces the levels of pMEK and pERK in a dose-dependent and time-dependent manner. MEK-IN-5 induces apoptosis in MDA-MB-231 cells .
    MEK-IN-5
  • HY-161966

    Apoptosis Reactive Oxygen Species (ROS) VEGFR Cancer
    VEGFR-2-IN-52 (compound 14d) is a potent VEGFR-2 inhibitor with an IC50 value of 191.1 nM. VEGFR-2-IN-52 decreases the protein expression of p-VEGFR-2, MMP9, p-ERK1/2 and p-MEK1. VEGFR-2-IN-52 shows cytotoxicity. VEGFR-2-IN-52 induces apoptosis and cell cycle arrest at G0/G1 phase. VEGFR-2-IN-52 increases the levels of ROS .
    VEGFR-2-IN-52
  • HY-202699

    Ras Apoptosis Cancer
    SHOC2-RAS PPI-IN-1 (compound 6) is a non-covalent competitive inhibitor targeting the interaction between SHOC2 and RAS proteins. SHOC2-RAS PPI-IN-1 has an IC50 of 0.048 μM and a KD of 0.065 μM for NRAS Q61R. SHOC2-RAS PPI-IN-1 can inhibit the activity of the SMP phosphatase complex, leading to increased CRAF S259 phosphorylation levels, thereby blocking the MAPK signaling pathway (such as reducing the levels of pMEK and pERK), inducing tumor cell cycle arrest and apoptosis. SHOC2-RAS PPI-IN-1 can be used for targeted research on malignant tumors such as melanoma and colorectal cancer with NRAS Q61R mutations .
    SHOC2-RAS PPI-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: